Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.62 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | QDPR | P09417 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1458622 | 0.98 | HTR2C (0.64) | HTR2CSLC18A3SIGMAR1SLC6A2SLC6A3 | |
| SCHEMBL2410760 | 0.89 | HTR3A (0.62) | HTR2CSLC6A2SLC6A3HTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL4573020 | 0.87 | HTR3A (0.61) | HTR2CSLC6A2SLC6A3SLC6A4HTR3A | |
| SCHEMBL29940424 | 0.86 | SLC6A3 (0.53) | HTR2CSLC6A2SLC6A3SLC6A4ADRA1A | |
| SCHEMBL1067433 | 0.86 | SLC6A3 (0.53) | HTR2CSLC6A2SLC6A3SLC6A4ADRA1A | |
| SCHEMBL29998694 | 0.85 | SLC6A3 (0.51) | HTR2CSLC18A3SIGMAR1SLC6A2SLC6A3 | |
| SCHEMBL3786501 | 0.82 | HDAC4 (0.52) | HTR2CSLC6A2SLC6A3SLC6A4ADRA1A | |
| SCHEMBL3790814 | 0.82 | SLC6A3 (0.50) | HTR2CSLC6A2SLC6A3SLC6A4ADRA1A | |
| SCHEMBL31352453 | 0.81 | SLC6A3 (0.51) | HTR2CSLC6A2SLC6A3SLC6A4ADRA1A | |
| SCHEMBL3695746 | 0.80 | DRD2 (0.62) | SLC6A2SLC6A3SLC6A4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| EP-4731223-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | Universitat De Barcelona (ES) | 2026-04-29 | — | — | EP | disclosed |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250109103-A1 | (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | UNIWERSYTET JAGIELLONSKI (PL) | 2025-04-03 | — | — | US | disclosed |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2025-03-11 | — | — | US | disclosed |
| CN-115362151-B | Arylpiperidines as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2025-02-11 | — | — | CN | disclosed |
| WO-2024261340-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | UNIVERSITAT DE BARCELONA (ES) | 2024-12-26 | — | — | WO | disclosed |
| US-12139458-B2 | (2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases | UNIWERSYTET JAGIELLONSKI (PL) | 2024-11-12 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1164574-C | Phenoxypropylamine compounds | ������ҩ��ʽ���� | 2004-09-01 | — | — | CN | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| CN-1378533-A | Phenoxypropylamine compounds | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2002-11-06 | — | — | CN | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
| WO-1998002432-A1 | BICYCLIC COMPOUNDS FOR CONTROLLING MICTURITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885SLC18A3 162/4885SIGMAR1 50/4885 |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | HTR2C 716/4885SLC18A3 3852/4885SIGMAR1 480/4885 |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | HTR2C 3014/4885SLC18A3 2364/4885SIGMAR1 800/4885 |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | HTR2C 4265/4885SLC18A3 1845/4885SIGMAR1 3780/4885 |
| US-12139458-B2 | (2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases | TRPV5, P2RX5, TRPV1 | HTR2C 1090/4885SLC18A3 1744/4885SIGMAR1 2130/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | HTR2C 235/4885SLC18A3 919/4885SIGMAR1 2679/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885SLC18A3 162/4885SIGMAR1 50/4885 |
| US-20250109103-A1 | (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | TRPV5, SCN5A, P2RX5 | HTR2C 1208/4885SLC18A3 1936/4885SIGMAR1 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.